All In Biotech

Drug Trial Radar · NCT05267613

Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.

A Phase III Study to Assess the Efficacy and Safety of NEXIUM for Maintenance of Healing of Erosive Esophagitis in Pediatric Patients 1 to 11 Years of Age

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

53

Actual

Start

Jul 1, 2022

Primary completion

Aug 10, 2026

Study completion Aug 10, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
IQVIA RDS Inc.; Calyx; Laboratory Corporation of America; Medidata Solutions; Thermo Fisher Scientific, Inc; CISCRP; Quipment Inc.; Little Journey Ltd.
First posted
Mar 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to compare the safety and efficacy of two doses of Nexium in maintaining healing of erosive esophagitis in patients 1 to 11 years of age.

Conditions

  • Erosive Esophagitis

Interventions

  • Nexium 20mgDrug

    Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.

  • Nexium 10mgDrug

    Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Presence / absence of Erosive EsophagitisTime frame: Week 24 (end of 16-week maintenance phase)

Locations

41 sites in 10 countries. Site status is shown where the registry gives one.

  • Research Site

    Mobile, Alabama

  • Research Site

    Sacramento, California

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Carmel, Indiana

  • Research Site

    Shreveport, Louisiana

  • Research Site

    The Bronx, New York

  • Research Site

    Akron, Ohio

  • Research Site

    Cleveland, Ohio

  • Research Site

    Milwaukee, Wisconsin

  • Research Site

    Córdoba, Argentina

  • Research Site

    Córdoba, Argentina

  • Research Site

    Paraná, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    Clayton, Australia

  • Research Site

    Namur, Belgium

  • Research Site

    Athens, Greece

  • Research Site

    Thessaloniki, Greece

  • Research Site

    Thessaloniki, Greece

  • Research Site

    Messina, Italy

  • Research Site

    Naples, Italy

  • Research Site

    Naples, Italy

  • Research Site

    Roma, Italy

  • Research Site

    Roma, Italy

  • Research Site

    Vilnius, Lithuania

  • Research Site

    Coimbra, Portugal

  • Research Site

    Lisbon, Portugal

  • Research Site

    Lisbon, Portugal

  • Research Site

    Lisbon, Portugal

  • Research Site

    Porto, Portugal

  • Research Site

    Porto, Portugal

  • Research Site

    Viana do Castelo, Portugal

  • Research Site

    Badalona, Spain

  • Research Site

    Santiago de Compostela, Spain

  • Research Site

    Seville, Spain

  • Research Site

    Seville, Spain

  • Research Site

    Hà Nội, Vietnam

  • Research Site

    Hanoi, Vietnam

  • Research Site

    Hanoi, Vietnam

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.